A review of Pfizer’s request for approval of its COVID-19 vaccine will likely be completed by January 2022, U.S. drug regulators announced Friday. The U.S. Food and Drug Administration (FDA) agreed to make the request a priority. FDA officials in December 2020 granted emergency use authorization to COVID-19 jabs from Pfizer and Moderna. The only other shot that has since been authorized for use in the United States is one from Johnson & Johnson. All three companies have asked for or intend to ask for full approval, which requires more data and a more thorough review. Dr. Janet Woodcock, the acting commissioner of food and drugs for the FDA, said regulators are targeting January 2022 to be done with the review, but the target “does not mean approval will not happen before that time.” “Quite to the contrary, the review of this BLA has been ongoing, is among the highest …